Annual Conference of Indian Society for Neuro-Oncology 2016

Not rated from 0 reviews
0% of guests recommend


People interest: 0

Mon, 16 Apr 2001 to Wed, 16 Apr 2003, 00:00

Start Time:





The Annual Conference of Indian Society for Neuro-Oncology, organized by the Kuoni Destination Management will take place from 1st April to the 3rd April 2016 at the Hyderabad International Convention Centre (HICC) in Hyderabad, India. The conference will cover areas like Cell biology and signaling,Epidemiology,Quality of life,Immunology and immunotherapy and In vitro / in vivo models and many more.


<ul><li>Largest annual congregation of neuro-oncology specialists- neurosurgeons, radiation oncologists, medical oncologists, neurologists, basic scientists.</li><li>Ab Guha Oration by past SNO president and Director of Neuro-oncology programme at Harvard.</li><li>Key note sessions on the theme of the conference namely- Emerging WHO classification of brain tumors &amp; Benign brain tumors- Surgical and radio- surgical management.</li><li>&ldquo;Do not miss&rdquo; sessions on the latest path breaking research in neuro-oncology.</li><li>Best Indian research being presented as poster and oral presentations.</li><li>Best International and national experts to debate on key issues in neurooncology</li></ul>
<p><strong>Abstracts must be submitted on-line via the website.</strong></p><p><strong>Abstracts sent by mail, fax or e-mail will NOT be accepted.</strong></p><p><strong>Deadline abstract submission: 1st March, 2016.</strong></p><p><strong>The optimal Browser for submission is MS INTERNET EXPLORER.</strong></p><h6>Abstract Regulations</h6><p>With the submission of an abstract to ISNOCON 2016, the presenting author:</p><ul><li>confirms that all authors are aware of and agree to the content of the abstract and support the data presented;</li><li>accepts to be the contact person for all correspondence about the abstract and inform co-authors about its status;</li><li>warrants that the data and conclusions presented in the abstract have not been published prior to the date of the ISNOCON. Abstracts containing previously published material will be rejected;</li><li>states that for studies involving human or animal subjects, permission has been obtained from the relevant regulatory authority, and properly informed consent give where appropriate;</li><li>accepts responsibility for the accuracy of the submitted abstract;</li><li>acknowledges that once the abstract is submitted, changes, corrections or rewording are possible until deadline of abstract submission <strong>(1st March, 2016);</strong></li></ul><p>Careful typing and proof-reading are essential as the abstract will appear, if accepted, as submitted.</p><h6>Affirmation regarding Registration</h6><p><strong>Important Note</strong>: At least 1 author (presenting author) of this abstract is obliged to register and pay the congress registration fee <strong>within 3 weeks</strong> after notification on acceptance. In the event of non-fulfillment the abstract will be <strong>withdrawn</strong> by the organisers.</p><h6>Acceptance and Selection of Abstracts</h6><p>All submitted abstracts will be reviewed by the Scientific Programme Committee in <strong>March 2016</strong>, and authors will be notified by email at the latest in mid March 2016. Abstract selection: Some accepted abstracts will be selected for oral presentation, some will be presented as posters.</p><h6>Abstract Format</h6><ul><li>The abstract must be submitted in good English.</li><li>The text must not exceed 2500 characters excluding spaces, title and authors.</li><li>A maximum of two institutions per author is allowed.</li><li>No more than 10 authors can be listed.</li><li>No tables, no graphs or illustrations are allowed.</li><li>No literature must be cited.</li></ul><h6>Submission topics</h6><p>Please select only ONE topic that refers to the main subject of your abstract</p><ol><li>Cell biology and signaling</li><li>Epidemiology</li><li>Quality of life</li><li>Immunology and immunotherapy</li><li>In vitro / in vivo models</li><li>BIOMARKERS</li><li>Neuroimaging of brain tumours</li><li>Glioblastom and Anaplastic gliomas</li><li>Low grade gliomas</li><li>Pediatric brain tumours</li><li>Meningiomas</li><li>Spinal cord tumours</li><li>Brain and leptomeningeal metastases</li><li>Neurotoxicity and neuroprotection</li><li>Paraneoplastic neurological syndromes</li><li>Supportive and palliative care</li><li>Primary central nervous system lymphoma (PCNSL)</li><li>New developments in surgery</li><li>New developments in radiotherapy</li><li>New developments in drug delivery</li><li>Miscellaneous</li></ol>


Not rated
Based on 0 review
Very Good
No Review
You must log in to write review
from $0.00

Start Time:


Extra prices:

{{ type.price }}%
{{ formatMoney(type.price) }}
  • {{total_price_html}}
  • {{pay_now_price_html}}
0 Review